Super-Oxidized Solution (SOS) Therapy for Infected Diabetic Foot Ulcers

Author(s): 
Luca Dalla Paola, MD; Enrico Brocco, MD; Antonella Senesi, MD, PhD; Maurizio Merico, MD; Daniele De Vido, MD; Roberta Assaloni, MD; Roberto DaRos, MD

Chronic wounds are a great burden to the healthcare system and account for approximately $20 billion in healthcare costs annually in the United States.1 Foot ulceration is the precursor to approximately 85% of all diabetic amputations, and it is estimated that 14%–20% of patients with foot ulcers will have to undergo amputation.2 Infection of the ulcer increases the risk of amputation.3 If patients with ulcers are initially treated by a multidisciplinary team, major amputations can be prevented in 80%–90% of cases of limb-threatening ischemia and in 95% of patients with infection.4–7 This is significant, because amputations are related to high morbidity and mortality, costing up to $60,000 per patient.8,9
The most widely used therapies for treating foot ulcers are operative procedures and systemic antibiotics, highlighting the importance of infection control.10–13 Topical antiseptics are used to reduce the microbial load in both intact skin and in wounds, but their role in the treatment of diabetic foot ulcers has yet to be determined.14 Antiseptics have been used in preference to topical antibiotics because of concerns about the development of bacterial resistance. However, the cytotoxic effects of these agents on the host’s dermal and epidermal cells may affect the wound healing process.15
Super-oxidized solutions may represent an alternative to the currently available antiseptics for the disinfection of skin and wounds.16–19 These solutions are electrochemically processed aqueous solutions manufactured from pure water and sodium chloride (NaCl). During the electrolysis process, water molecules are pulled apart, and reactive species of chlorine and oxygen are formed.20 Different super-oxidized solutions have different properties.21 Increased acidity or alkalinity and high concentrations (> 100 ppm) of free available chlorine (FAC) correlate with increased corrosiveness and toxicity of a solution. Another problem with these solutions has been stability, which can range from a few hours to several days.
Recently, a neutral pH super-oxidized solution (SOS; Dermacyn® Wound Care, Petaluma, Calif, USA) became available in Europe. According to the manufacturer, this solution has a low FAC (< 80 ppm) and is stable for more than 1 year. This solution has shown broad antimicrobial activity even against antibiotic-resistant strains.20,22 It has also been reported that this solution does not induce skin, dermal, or systemic toxicities in animal models.20 Preliminary data in humans also suggest efficacy and safety.23,24
To evaluate the role of this novel solution in infected diabetic foot lesions, the authors compared SOS with 10% povidone iodine solution (PI) as the adjuvant local antimicrobial therapy in a standard treatment program. The program included operative procedures, systemic antibiotic therapy, and offloading techniques.
The main objective was to evaluate the reduction in the number of bacterial species during the course of treatment. Other variables evaluated included the time to lesion healing, the incidence and types of operative outcomes, and adverse events.

References: 

1. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22(3):382–387.
2. Motta G. The first 60 days of PPS: managing wound care medical supplies. The Remington Report. Nov/Dec. 2000.
3. Wagner A, Reike H, Angelkort B. Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections. Dtsch Med Wochenschr. 2001;126(48):1353–1356.
4. Lipsky BA. Infectious problems of the foot in diabetic patients. In: Bowker JH, Pfeifer MA, eds. Levin and O’Neal’s The Diabetic Foot. 6th ed. St Louis, Mo: Mosby; 2001:467–480.
5. Rosenblum BI, Pomposelli FB Jr, Giurini JM, et al. Maximizing foot salvage by a combined approach to foot ischemia and neuropathic ulceration in patients with diabetes. A 5-year experience. Diabetes Care. 1994;17(9):983–987.
6. Holstein P, Ellitsgaard N, Olsen BB, Ellitsgaard V. Decreasing incidence of major amputations in people with diabetes. Diabetologia. 2000;43(7):844–847.
7. Brem H, Jacobs T, Vileikyte L, et al. Wound-healing protocols for diabetic foot and pressure ulcers. Surg Technol Int. 2003;11:85–92.
8. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005;366(9498):1719–1724.
9. Muradin GS, Bosch JL, Stijnen T, Hunink MG. Balloon dilation and stent implantation for treatment of femoropopliteal arterial disease: meta-analysis. Radiology. 2001;221(1):137–145.
10. Gibbons GW. The diabetic foot: amputations and drainage of infection. J Vasc Surg. 1987;5(5):791–793.
11. Armstrong DG, Frykberg RG. Classifying diabetic foot surgery: toward a rational definition. Diabet Med. 2003;20(4):329–331.
12. Dalla Paola L, Faglia E, Caminiti M, et al. Ulcer recurrence following first ray amputation in diabetic patients: a cohort prospective study. Diabetes Care. 2003;26(6):1874–1878.
13. Faglia E, Dalla Paola L, Clerici G, et al. Peripheral angioplasty as the first-choice revascularization procedure in diabetic patients with critical limb ischemia: prospective study of 993 consecutive patients hospitalized and followed between 1999 and 2003. Eur J Vasc Endovasc Surg. 2005;29(6):620–627.
14. Nelson EA, O’Meara S, Craig D, et al. A series of systematic reviews to inform a decision analysis for sampling and treating infected diabetic foot ulcers. Health Technol Assess. 2006;10(12):1–238.
15. Drosou A, Falabella A, Kirsner S. Antiseptics on wounds: an area of controversy. WOUNDS. 2003;15(5):149–166.
16. Sekiya S, Ohmori K, Harii K. Treatment of infectious skin defects or ulcers with electrolyzed strong acid aqueous solution. Artif Organs. 1997;21(1):32–38.
17. Ohno H, Higashidate M, Yokosuka T. Mediastinal irrigation with superoxidized water after open-heart surgery: the safety and pitfalls of cardiovascular surgical application. Surg Today. 2000;30(11):1055–1056.
18. Inoue Y, Endo S, Kondo K, Ito H, Omori H, Saito K. Trial of electrolyzed strong acid aqueous solution lavage in the treatment of peritonitis and intraperitoneal abscess. Artif Organs. 1997;21(1):28–31.
19. Sakashita M, Iwasawa A, Nakamura Y. Antimicrobial effects and efficacy on habitually hand-washing of strong acidic electrolyzed water—a comparative study of alcoholic antiseptics and soap and tap water. Kansenshogaku Zasshi. 2002;76(5):373–377.
20. Gutiérrez AA. The science behind stable, super-oxidized water. Exploring the various applications of super-oxidized solutions. WOUNDS. 2006;18(1 Suppl):7–10.
21. Sampson MN, Muir AV. Not all super-oxidized waters are the same. J Hosp Infect. 2002;52(3):228–229.
22. Landa-Solis C, González-Espinosa D, Guzman-Soriano B, et al. Microcyn: a novel super-oxidized water with neutral pH and disinfectant activity. J Hosp Infect. 2005;61(4):291–299.
23. Miranda-Altamirano A. Reducing bacterial infectious complications from burn wounds. A look at the use of Oculus Microcyn60 to treat wounds in Mexico. WOUNDS. 2006;18(1 Suppl):17–19.
24. Wolvos TA. Advanced wound care with stable, super-oxidized water. A look at how combination therapy can optimize wound healing. WOUNDS. 2006;18(1 Suppl):11–13.
25. Armstrong DG, Lavery LA, Harkless LB. Validation of a diabetic wound classification system. The contribution of depth, infection, and ischemia to risk of amputation. Diabetes Care. 1998;21(5):855–859.
26. Apelqvist J, Bakker K, van Houtum WH, Nabuurs-Franssen MH, Schaper NC. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes Metab Res Rev. 2000;16(Suppl 1):S84–92.
27. Allie D. Super-oxidized Dermacyn in lower-extremity wounds. WOUNDS. 2006;18(1 Suppl):3–6.
28. Boulton AJ, Meneses P, Ennis WJ. Diabetic foot ulcers: a framework for prevention and care. Wound Repair Regen. 1999;7(1):7–16.
29. Schultz GS, Sibbald RG, Falanga V, et al. Wound bed preparation: a systematic approach to wound management. Wound Repair Regen. 2003;11(Suppl 1):S1–S28.
30. Veverkova L, Jedlicka V, Vesely M, et al. Methicillin resistant-Staphylococcus aureus—Problem in health care. J Wound Healing. 2005;2:201–202.
31. Tanaka H, Hirakata Y, Kaku M, et al. Antimicrobial activity of superoxidized water. J Hosp Infect. 1996;34(1):43–49.
32. Kiura H, Sano K, Morimatsu S, et al. Bactericidal activity of electrolyzed acid water from solution containing sodium chloride at low concentration, in comparison with that at high concentration. J Microbiol Methods. 2002;49(3):285–293.
33. Yahagi N, Kono M, Kitahara M, et al. Effect of electrolyzed water on wound healing. Artif Organs. 2000;24(12):984–987.
34. Derbyshire A. The use of combination treatments and dressings for a traumatic wound. Br J Nurs. 2004;13(16):987–993.



Post new comment

  • Lines and paragraphs break automatically.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Use to create page breaks.

More information about formatting options

Image CAPTCHA
Enter the characters shown in the image.